The current practice of platelet aggregation inhibition in acute coronary syndrome is reviewed. The specific dosing and its clinical usefulness of each medication are considered. The author is drawing attention to the fact, that the dosing scheme used in the early phase 3 trials may not have been optimal as proven in later trials. The hyporeactivity against both acctilsalicilic acid and clopidogrel treatment is existing and maybe called resistance. Its clinical importance in clinical outcomes is to be determined in later investigations. Because of the probable relationship between resistance and clinical outcomes the measurement of platelet reactivity by a reliable rapid bedside tool may be important in the future. Also the new platelet aggregation inhibitors under development are reviewed.
|Translated title of the contribution||Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations|
|Number of pages||9|
|Publication status||Published - Mar 16 2008|
ASJC Scopus subject areas